研究单位：[1]Betta Pharmaceuticals Co., Ltd.[2]Peking Union Medical College Hospital,Beijing,Beijing,China,100032[3]Affiliated hospital of Hebei university,Baoding,Hebei,China,050031[4]Hunan cancer hospital,Changsha,Hunan,China,410031[5]Central hospital affiliated to shandong first medical university,Jinan,Shandong,China,250013
研究目的：
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
